gene profiling 1
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) improve glycaemic control, facilitate clinically meaningful weight loss, improve survival, and reduce the risk of renal failure and major adverse cardiovascular events
Endocrine, Metabolic & Immune Disorders Drug Targets
To address how Klotho regulates GR protein expression, we performed an in vitro study which showed that culturing with secreted Klotho-deficient medium decreased Nrf2 expression levels while treatment with secreted Klotho increased Nrf2 expression in H9c2 cells (Figure 8), suggesting that secreted Klotho regulates Nrf2 expression
It is a peptide that may affect growth hormone signaling, recovery perception, sleep, appetite, glucose-related factors, and body composition goals
GLP-1RAs and clinical trials in NAFLD Lixisenatide In a systematic meta-analysis including 12 randomized controlled trials (RCTs) comparing lixisenatide to placebo or active interventions in T2D, lixisenatide was reported to normalize levels of alanine aminotransferase (ALT) in a greater proportion of overweight and obese patients with T2D than comparators (54)